TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates, to combat neurodegenerative diseases, today announced the appointment of Dr Mike Hutton to its Scientific Advisory Board (SAB).
To continue reading click here
